A phase II clinical trial, in which AD patients were treated with Apabetalone (RVX-208) (a molecule that stimulates APOA-I gene expression) for 12 weeks, showed that plasma levels of Aβ increased compared to the baseline levels (McNeill, 2010). This evidence concerns the gene APOA1 and Alzheimer disease.